End-stage Heart Failure Clinical Trial
Official title:
Carmat Total Artificial Heart Early Feasibility Study
NCT number | NCT04117295 |
Other study ID # | CAR2019-US |
Secondary ID | |
Status | Suspended |
Phase | N/A |
First received | |
Last updated | |
Start date | July 12, 2021 |
Est. completion date | January 2026 |
Verified date | December 2023 |
Source | Carmat SA |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Feasibility study of the Carmat TAH as a treatment for transplant-eligible patients in severe, end-stage heart failure.
Status | Suspended |
Enrollment | 10 |
Est. completion date | January 2026 |
Est. primary completion date | June 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Must be 18 years of age or older at the time of informed consent 2. Anatomic compatibility confirmed using 3D imaging (CT-scan). 3. Inotrope dependent (with documented attempt to wean) or cardiac Index (CI) < 2.2 L/min/m2 if inotropes are contra-indicated (heart failure due to restrictive or constrictive physiology). 4. On Optimal Medical Management as judged by the investigator based on current Heart Failure practice guidelines (ESC/AHA). 5. Eligible for biventricular Mechanical Circulatory Support according to ISHLT guidelines for mechanical circulatory support: 1. Biventricular failure with at least two of the following hemodynamic/ echocardiographic measurements implying right heart failure: RVEF =30%; RVSWI =0.25mmHg*L/m2; TAPSE =14mm; RV-to-LV end-diastolic diameter ratio >0.72; CVP >15 mmHg; CVP-to-PCWP ratio >0.63; Tricuspid insufficiency grade 4; PAPi<2 2. Treatment-refractory recurrent and sustained ventricular tachycardia or ventricular fibrillation in the presence of untreatable arrhythmogenic pathologic substrate. 3. Heart failure due to restrictive or constrictive physiology (e.g., hypertrophic cardiomyopathy, cardiac amyloidosis / senile or other infiltrative heart disease). 6. Patient has signed the informed consent, has full understanding of procedures, and is committed to following study requirements. 7. Eligible for cardiac transplantation Exclusion Criteria: 1. Known intolerance to anticoagulant or antiplatelet therapies or known Heparin Induced Thrombocytopenia. 2. Presence of any non-temporary mechanical circulatory support 3. Presence of temporary mechanical circulatory support such as Impella (all types) or IABP with a duration greater than 21 days 4. Presence of ECMO with a duration greater than 7 days 5. Patient is intubated and unconscious, or intubated and not awake 6. Coagulopathy defined by platelets < 100k/µl or INR = 1.5 not due to anticoagulant therapy. 7. Cerebrovascular accident < 3 months or symptomatic or a known > 80% carotid stenosis. 8. Known abdominal or thoracic aortic aneurysm > 5 cm that has not been treated. 9. Severe end-organ dysfunction as per any of the following criteria: 1. Total bilirubin > 2.5 mg/dl or cirrhosis evidenced by ultrasound, CT-scan and positive biopsy 2. eGFR < 30ml/min/1.73m2 or the need for chronic renal replacement therapy 10. History of severe Chronic Obstructive Pulmonary Disease with FEV1/FVC <0.7, or FEV1<50% predicted or severe restrictive lung disease. 11. Recent blood stream infection (<7 days). 12. Documented amyloid light-chain (AL amyloidosis). 13. Hemodynamically significant peripheral vascular disease with documented ankle- brachial pressure index (ABPI) <0.3. 14. Illness, other than heart disease, that would limit survival to less than 2 years. 15. Irreversible cognitive dysfunction, psychosocial issues or psychiatric disease, likely to impair compliance with the study protocol and TAH management that in the opinion of the investigator could interfere with the ability to manage the therapy (i.e. non-compliance to heart failure therapy, uncontrolled diabetes, mental health issue, etc.). 16. Current or planned pregnancy or breast feeding (woman of childbearing age will have to show negative pregnancy test). 17. Patient is currently enrolled or has participated in the last 30 days in another therapeutic or interventional clinical study that is likely to confound the study results or affect the study. |
Country | Name | City | State |
---|---|---|---|
United States | Baylor University Medical Center | Dallas | Texas |
United States | Duke University Medical Center | Durham | North Carolina |
United States | University of Louisville Jewish Hospital | Louisville | Kentucky |
United States | VCU Medical Center | Richmond | Virginia |
Lead Sponsor | Collaborator |
---|---|
Carmat SA |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Survival | Proportion of patients surviving on the Carmat TAH | 180 days | |
Secondary | Survival without Permanent Neurologic Deficit | Proportion of patients surviving post implant without a permanent disabling stroke (Modified Rankin Scale >3) | 180 days | |
Secondary | Post transplant survival | Proportion of patients surviving 30 days post-transplant | 30 days | |
Secondary | Change in functional status | New York Heart Association (NYHA) functional classification (regression scale I, II, III, IV) | 180 days | |
Secondary | Change in functional status measured by the Six Minutes Walk Test | The 6-min walk test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk distance provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise. | 180 days | |
Secondary | Generic health status change | Measured with the EuroQol EQ-5D questionnaire, a descriptive system of health-related quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses (EQ-5D-5L). The responses record five levels of severity (1:no problems; 2:slight problems; 3:moderate problems 4:severe problems; 5:extreme problems) within a particular EQ-5D dimension.
Measured with the Kansas City Cardiomyopathy Questionnaire, a self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. |
180 days | |
Secondary | Adverse Events | Adverse Event Rates will be captured per the INTERMACS definitions | 180 days | |
Secondary | Hospital readmission rate | Rate of unplanned readmissions to the hospital | 180 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06063811 -
Ventricular Tachycardia Ablation in LVAD Patients
|
||
Withdrawn |
NCT04782245 -
Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List
|
Phase 2 | |
Active, not recruiting |
NCT04351945 -
Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors
|
||
Recruiting |
NCT03966313 -
Perioperative Modification of Hemostasis During Ventricular Assist Device Implantation
|
||
Recruiting |
NCT02592499 -
Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure
|
N/A | |
Active, not recruiting |
NCT00483197 -
VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal Trial
|
Phase 3 | |
Active, not recruiting |
NCT00490321 -
VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy
|
Phase 3 | |
Completed |
NCT04543747 -
Mechanical Circulatory Support Korea Post Market Surveillance Study (PMS)
|
||
Recruiting |
NCT04293575 -
Transcatheter Mitral Valve Repair as Bridge Therapy to Heart Transplantation
|
||
Recruiting |
NCT04641416 -
Noninvasive Cardiovascular Diagnosis of Patients With Fully Magnetically Levitated Blood Pumps
|
||
Completed |
NCT00490347 -
VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Feasibility Trial
|
Phase 2 | |
Completed |
NCT05353816 -
Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial
|
N/A | |
Completed |
NCT04480151 -
ECLS Versus IMPELLA™ as Bridge to LVAD (ECI-BLAD)
|
||
Recruiting |
NCT04205760 -
Preoperative Nutritional Optimization and Physical Exercise for Patients Scheduled for Elective Implantation for a Left-Ventricular Assist Device
|
Phase 3 | |
Recruiting |
NCT06345521 -
Etablishment of Follow-up System and End-Stage Heart Registration Platform for Pediatric Heart Failure
|
||
Recruiting |
NCT04768322 -
LVAD Versus GDMT in Ambulatory Advanced Heart Failure Patients
|
N/A | |
Completed |
NCT02248974 -
Development & Testing of a Decision Aid for LVAD Placement
|
N/A | |
Completed |
NCT06152562 -
Evaluation of Platelet Therapy Response in Left Ventricular Assist Device Patients
|
||
Completed |
NCT05928273 -
Corheart 6 LVAS LTFU
|
N/A | |
Recruiting |
NCT04951999 -
AssocIation of PULSatility and Occurrence of Complications Related to Mechanically Assisted Circulatory Support
|
N/A |